Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Sleep Disorders Channel is supported through educational grants from Alkermes and Takeda.

VJNeurology is an independent medical education platform. Channel supporters have no influence over the production of content.

Share this video  

ECNP 2021 | Treating restless leg syndrome: the present and the future

Diego Garcia-Borreguero, MD, PhD, Sleep Research Institute, Madrid, Spain, shares an overview of the treatment landscape for restless leg syndrome (RLS). Currently, dopamine agonists are widely used for the treatment of RLS, including ropinirole, rotigotine, and pramipexole. However, pharmacological tolerance and dopamine augmentation frequently prevent their long-term use. Dr Garcia-Borreguero emphasizes the need for new therapeutic options in this space, highlighting several lines of research underway. Intravenous iron and Alpha-2-delta calcium channel ligands can be effective for RLS. Perampanel and dipyridamole are also promising non-dopaminergic agents in development. This interview took place at the European College of Neuropsychopharmacology congress 2021.

Choose your cookie settings

VJNeurology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.